Disagree with your above comment.
PXS has $18.4 million cash sitting in the bank and they will be cashflow positive end of 2021 based of current projections.
This is with the exclusion of milestone payments of $15 million US from their partner Chiesi.
FDA product line in the backend with cashflow positive outlook plus milestones and valued at $0.09 cents a share with only 392 million shares outstanding.
I think those Bollinger bands will squeeze on investors getting in around these prices.
Ann: Appendix 4C - quarterly, page-3
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
